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We are experiencing very exciting days in thoracic 
oncology thanks to the advent of new promising 
compounds which will shortly lead to a radical 
change in the treatment algorithm of non-small 
cell lung cancer (NSCLC). Targeted therapies, 
including epidermal growth factor receptor 
(EGFR) and echinoderm microtubule-associated 
protein-like 4–anaplastic lymphoma kinase 
(EML-ALK4) tyrosine kinase inhibitors (TKIs), 
represent the standard first-line therapy for 
EGFR-mutated or EML-ALK translocated 
NSCLC, showing a clear superiority compared 
with platinum-based chemotherapy [Bronte et al. 
2014; Rolfo et  al. 2014]. Although targetable 
‘oncogene addicted’ tumors affect only a minority 
of patients, accounting for about 15–20% of the 
overall NSCLC population, other oncogenic 
drivers such as ROS1, cMet, human epidermal 
growth factor receptor type 2 (HER-2) and BRAF 
have been recently identified and clinical trials are 
investigating the activity of new targeted agents in 
order to extend the number of patients who may 
benefit from tailored approaches [Passiglia et al. 
2015a; Bronte et  al. 2010]. However, ‘non- 
oncogene addicted’ tumors currently represent 
the majority of NSCLC cases, classified into 
squamous versus nonsquamous histotype. For 
them, histology-driven platinum-based combina-
tions with gemcitabine, pemetrexed and/or beva-
cizumab remain the standard first-line treatment, 
reaching a survival plateau of 14–16 months, 
including maintenance strategy [Paz-Ares et  al. 
2013; Lopez-Chavez et  al. 2012]. Docetaxel, 
pemetrexed and erlotinib are recommended as 
equal second-line options [Peters et  al. 2012], 
while erlotinib represent the only drug approved 
as third-line therapy on the basis of the BR21 trial 
results [Shepherd et al. 2005].
The question of comparative efficacy between 
EGFR-TKI and single agent chemotherapy in 
wildtype NSCLC populations has been addressed 
by several trials and meta-analysis [Zhao et  al. 
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2014; Li et  al. 2014], producing controversial 
results. Therefore, the choice of the best second-
line therapy remains a matter of discussion and 
ongoing research. Combining anti-angiogenic 
agents with chemotherapy has recently emerged 
as a very promising strategy in this setting of 
patients. Two phase III randomized studies, com-
paring the oral triple TKI, nintedanib, and the 
anti vascular endothelial growth factor receptor 2 
(VEGFR2) monoclonal antibody, ramucirumab, 
both in combination with docetaxel versus doc-
etaxel alone, have displayed a significant survival 
advantage in favor of the combination arms in 
patients who progressed to platinum-based chem-
otherapy [Reck et  al. 2014; Garon et  al. 2014], 
leading to their approval by regulatory agencies.
In this review we focus our attention on nint-
edanib, which has been recently approved by 
European Medicine Agency (EMA) for the sec-
ond-line treatment of NSCLC patients with ade-
nocarcinoma subtype. We briefly describe the 
angiogenesis process and preclinical activity of 
such compound in NSCLC models. All clinical 
evidence emerging from phase I–III trials are sub-
sequently reported, with discussion of controver-
sial aspects of competition with the other 
compounds and ultimately looking at its best 
place in NSCLC therapy.
Angiogenesis of NSCLC
Cancer growth and its metastatic capability are 
sustained by angiogenesis, which is their lifeblood 
[Folkman, 1990]. Genetic and epigenetic events 
induce the ‘angiogenic switch’, a shift from a vas-
cular tumor phenotype to a neovascularization 
condition which lends strength to the mass, sim-
plifying the migration of endothelial cells and the 
metastatic process [Pallis and Syrigos, 2013]. In 
this event, the balance of pro-angiogenetic vascu-
lar endothelial growth factor (VEGF), epidermal 
growth factor (EGF), fibroblast growth factor α 
(TGF-α), platelet derived growth factor (PDGF), 
granulocyte-macrophage colony stimulating fac-
tor (GM-CSF), tumor necrosis factor α (TNF-
α), placenta growth factor (PIGF), cytokines 
such as interleukin (IL-1, IL-6, IL-8) and mono-
cyte chemotactic protein-1 (MCP-1), endothelin 
1 (ET-1), endothelin 2 (ET-2) and protease 
matrix metalloproteinases (MMPs), cathepsins, 
gelatinase A and B, stromelysin and urokinase-
type plasminogen activator (uPA), and anti-angi-
ogenetic factors such as thrombospondin-1 
(TSP-1), angiostatin moves in favor of the major 
secretion of pro-factors. Indeed, NSCLC tumor 
cells show the overexpression of VEGF, the most 
important vessel growth factor capable of control-
ling migration, proliferation, invasion and sur-
vival of endothelial cells, in both physiological 
and pathological ways [Jackson et al. 2010].
The signaling pathway, arising from the relation-
ship between VEGF and its receptors (VEGFR), 
acts alone or in synergy with platelet-derived 
growth factor (PDGF) receptors (PDGFRs), 
fibroblast growth factor (FGF) receptors (FGFR) 
and angiopoietin (Ang)/endothelial TEK tyrosine 
kinase (Tie2), and seems critical for the growth of 
new vessels and the tumor cell survival [Onimaru 
and Yonemitsu, 2011]. Several studies have indi-
cated that the tissue overexpression of VEGF and 
of these three molecules appears to be associated 
with poor prognosis and probable increase of 
angiogenesis, suggesting a potential prognostic 
role in NSCLC patients [Villaruz and Socinski, 
2015]. The expression of VEGF is also regulated 
by PDGF through autocrine mechanisms. A 
higher percentage of NSCLC patients with high 
PDGF tissue levels may have a major resistance 
to VEGF-targeted therapy. In order to confirm 
this, in vitro preclinical studies have shown a 
greater therapeutic efficacy by both VEGF and 
PDGF inhibition than inhibiting only VEGF. 
This evidence may also indicate the dependence 
of angiogenesis on the co-expression of VEGF 
and PDGF in NSCLC tumors. In addition, the 
concurrent overexpression of VEGF and FGF or 
Ang ligands seems to be likely involved in the 
regulation of angiogenesis and in a worse progno-
sis of NSCLC patients, instead of the high expres-
sion of VEGF alone [Piperdi et al. 2014]. Hypoxia, 
angiogenesis and the NSCLC development are 
part of a network of events that may be regulated 
by VEGF-targeted therapy.
Preclinical development of nintedanib
Nintedanib was identified during a program for 
small molecule inhibitors of angiogenesis and 
studies were extended to various solid tumors. 
Recent evidence shows that nintedanib is a potent 
endothelial cell proliferation inhibitor with a good 
safety profile – proven in both in vitro and in vivo 
studies.
Nintedanib is an indolinone derivative, multiple 
TKI. This molecule occupies the adenosine 
triphosphate (ATP) binding sites in the kinase 
domain of pro-angiogenic receptors, including 
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VEGFR-1, VEGFR-2, VEGFR-3, FGFR-1, 
FGFR-2, FGFR-3, PDGFR-α and PDGFR-β, 
inhibiting the downstream signaling pathways. 
Nintedanib also inhibits FMS-like tyrosine kinase 
3 (FLT3) and SRC family members, but does not 
affect other kinases such as insulin-like growth 
factor receptor (IGFR) and the epidermal growth 
factor receptor (EGFR) (Figure 1) [Rolfo et  al. 
2013]. In vitro studies showed that treatment with 
nintedanib induced proliferation arrest and apop-
tosis in three cell types involved in angiogenesis 
(endothelial cells, smooth muscle cells and peri-
cytes) through the inhibition of both AKT and 
mitogen-activated protein kinases (MAPK) sign-
aling pathways, resulting in an overexpression of 
the apoptosis marker cleaved caspase-3 [Hilberg 
et al. 2008].
These data have been confirmed by in vivo studies 
performed in human NSCLC xenografts. One of 
these studies analyzed the effects of nintedanib 
both as a single agent and in combination with 
standard chemotherapy, showing a potent inhibi-
tion of proliferation and increased apoptosis of 
tumor cells in xenografts that did not respond to 
platinum-based chemotherapy and bevacizumab. 
In addition, nintedanib reduced vessel permeabil-
ity and perfusion, microvessel density (CD31) 
and pericyte coverage (NG2), resulting in a potent 
antiangiogenic effect. The activity of nintedanib 
was not associated with an increased expression of 
the epithelial mesenchymal transition (EMT) 
markers, which is a common mechanism of resist-
ance to anti-angiogenic therapies [Kutluk Cenik 
et al. 2013]. Another recent study evaluating the 
cotreatment of nintedanib with small interfering 
RNAs (siRNAs) against six specific genes involved 
in EMT has shown that this molecule is able to 
induce reversal of EMT by the regulation of two 
mesenchymal genes, SYDE1 and ZEB1 [Huang 
et al. 2015].
The toxic potential of nintedanib has been thor-
oughly evaluated in a toxicological program 
including in vitro and in vivo studies. The majority 
of these studies showed a tolerable safety profile of 
this compound excluding any severe cardiovascu-
lar, respiratory, or neurological adverse effects as 
well as any mutagenic potential of nintedanib 
[Roth et al. 2015].
Evidence from clinical trials with nintedanib
Phase I and phase II trials
Nintedanib activity has been studied in different 
kinds of neoplasm such as ovarian cancer, 
NSCLC, breast cancer, glioblastoma, colorectal 
Figure 1. Nintedanib mechanism of action.
ATP, adenosine triphosphate; FGFR, fibroblast growth factor receptor; PDGFR, platelet-derived growth factor; VEGFR, 
vascular endothelial growth factor receptor 2.
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cancer, urothelial carcinoma, biliary tract carci-
noma, and head and neck cancer, which provided 
substantial information about the tolerability of 
this drug [Mross et al. 2010]. With regard to its 
use in advanced NSCLC, Doebele and colleagues 
investigated nintedanib use in combination with 
paclitaxel and carboplatin in chemotherapy-naïve 
advanced NSCLC [Doebele et al. 2012]. In this 
trial, 26 patients received nintedanib at the start-
ing dose of 50 mg twice daily on days 2–21 in 
association with paclitaxel at the dose of 200 mg/m2 
and carboplatin at area under the curve (AUC) 5 
on day 1 of each 21 day cycle. The treatment was 
well tolerated with only a few dose-limiting toxici-
ties such as liver enzyme elevations, thrombocyto-
penia, abdominal pain and rash that did not affect 
the pharmacokinetic (PK) parameters of the nint-
edanib or chemotherapeutic backbone.
The scientific community is also waiting for the 
results of another phase I/II study in which nint-
edanib was added to gemcitabine/cisplatin as 
first-line treatment of advanced or recurrent 
NSCLC, specifically of squamous histology to 
evaluate its activity in this group of patients. In 
another dose escalation phase I trial, nintedanib 
in association with pemetrexed was investigated 
in a cohort of 26 patients with advanced NSCLC 
previously treated with a first-line platinum-based 
chemotherapy. The schedule of treatment was 
nintedanib given at staring dose of 100 mg twice 
daily on days 2–21 in association with a standard 
dose of pemetrexed (500 mg/m2) on day 1 of a 21 
day cycle. The resultant maximum tolerated dose 
(MTD) of nintedanib was determined to be 200 
mg twice daily; similar to the previous studies, 
nintedanib showed a good safety profile [17 dose 
limiting toxicities (DLT)] with interesting clinical 
efficacy (1 complete response, 2 partial responses 
and 8 stable disease of 20 evaluable patients) 
[Ellis et al. 2010].
The same MTD of nintedanib (200 mg twice 
daily) was established in another Japanese trial 
[Daga et al. 2013], where similar efficacy results as 
the previous studies was found and showing proof 
of efficacy of this drug in an Asiatic population. In 
another more recent Asiatic experience, Okamoto 
and colleagues evaluated the combination of nint-
edanib with docetaxel in advanced NSCLC 
patients who had been previously treated. They 
found promising and encouraging safety and effi-
cacy results, obtaining a 73% of disease control 
rate and only 12 DLTs [Okamoto et  al. 2015]. 
The time-to-progression and objective response 
rate found in this study provided the rationale to 
continue investigation about this drug within large 
randomized controlled trials.
Phase III trials
With regard to the evaluation of nintedanib in a 
wider population, its efficacy was tested in two 
randomized controlled phase III trials, with the 
aim of improving the clinical result of the stand-
ard cytotoxic agents in advanced NSCLC treat-
ment. Reck and colleagues investigated the role of 
nintedanib (200 mg twice daily on days 2–21) in 
addition to docetaxel (75 mg/m2) on day 1 of 21 
day cycle compared with docetaxel (75 mg/m2) 
plus placebo in the LUME-Lung 1 trial. The pri-
mary endpoint was progression-free survival 
(PFS). PFS was assessed by an independent cen-
tral review, analyzed after 714 events in all 
patients. Overall survival (OS) was predefined as 
a key secondary outcome; other secondary out-
comes were investigator-assessed PFS, tumor 
response by central review and investigator assess-
ment, safety and tolerability. With regard to 
EGFR status evaluation, there was no preplanned 
subgroup analysis for this item because the test 
was not included in clinical practice at the time of 
the trial design.
The nintedanib plus docetaxel group showed a 
significantly longer PFS as determined by cen-
tral independent review than the control group 
[median PFS 3.4 versus 2.7 months, respec-
tively; hazard ratio (HR) 0.85; 95% confidence 
interval (CI) 0.75–0.96; p = 0.0019], with a 
more pronounced benefit in patients with ade-
nocarcinoma histology (median PFS 4.2 versus 
2.8 months, respectively; HR 0.84; 95% CI 
0.71–1.00; p = 0.0485). OS showed only a 
trend in favor of the combination (median OS 
10.1 versus 9.1 months; HR 0.94; 95% CI 0.83–
1.05; p = 0.272) in all histologies, with more 
benefit in the adenocarcinoma subgroup 
(median OS 12.6 versus 10.3 months, respec-
tively; HR 0.83; 95% CI 0.70–0.99; p = 0.0359) 
(Table 1). The tolerability profile was similar to 
that shown in phase I/II exploratory trials. 
Patients most commonly experienced diarrhea, 
increases of transaminases, nausea, decreased 
appetite and vomiting – all easily manageable by 
supportive treatment or dose reduction. Note 
that the combination of nintedanib plus doc-
etaxel increased not only PFS in all NSCLC 
Therapeutic Advances in Medical Oncology 8(3)
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histologies, but also improved OS even in the 
adenocarcinoma subgroup, including those 
patients who experienced progression of disease 
within 9 months of start of first-line therapy 
[Reck et al. 2014].
Nintedanib, at the same dose, was also investi-
gated in combination with pemetrexed (500 mg/m2) 
and compared with pemetrexed (500 mg/m2) plus 
placebo in the LUME-Lung 2 phase III con-
trolled randomized trial [Hanna et al. 2013]. The 
primary endpoint was the same (PFS) based on 
independent central review and a preplanned 
futility analysis was performed to verify if the pri-
mary endpoint was unlikely to be met. The study 
met its primary endpoint for the combination arm 
(4.4 versus 3.6 months compared with placebo; 
HR 0.83; 95% CI 0.70–0.99; p = 0.0435), 
although the recruitment was stopped prema-
turely and this difference has not translated into 
an OS benefit (12.2 versus 12.7 months, respec-
tively; HR 1.03; 95% CI 0.85–1.24; p = 0.7921). 
Also in this study, nintedanib showed relatively 
high increases in aspartate transaminase (AST) 
and alanine aminotransferase (ALT) liver 
enzymes and gastrointestinal events, but simple 
to resolve with standard medications.
Based on new knowledge in the field of molecular 
biology, interesting data could emerge from an 
ongoing phase III study [ClinicalTrials.gov iden-
tifier: NCT02299141] that is evaluating the effec-
tiveness of nintedanib in molecularly selected 
NSCLC patients, with investigation of the poten-
tial role of some genes (VEGFR1-3, PDGFR-A, 
PDGFR-B and FGFR1-3) that could be involved 
in the regulation of mechanisms of acquired 
resistance to anti-angiogenic agents.
Place of nintedanib in the current treatment 
algorithm of NSCLC
The results of the LUME-Lung 1 trial interrupted 
the negative trend of anti-angiogenic agent effi-
cacy in NSCLC. Since the therapeutic success 
obtained by bevacizumab in the first-line setting, 
several multi-TKIs, including sunitinib, sorafenib, 
vandetanib and motesanib, had been investigated 
in clinical trials, both as single agents or in combi-
nation with chemotherapy, but failing to demon-
strate any impact on the OS of NSCLC patients 
[Scagliotti et  al. 2010, 2012a, 2012b; Paz-Ares 
et  al. 2012; de Boer et  al. 2011; Herbst et  al. 
2010]. After several years of research, this is the 
first study showing a modest, but significant OS 
advantage in favor of a combination regimen over 
the standard single-agent therapy in NSCLC 
patients who progressed to first-line platinum 
chemotherapy [Reck et al. 2014]. Specifically, the 
addition of nintedanib to docetaxel seems to ben-
efit the subgroup of patients with adenocarci-
noma histology (median OS 12.6 versus 10.3 
months; HR 0.83; 95% CI 0.70–0.99; p = 
0.0359), including patients with poor prognosis 
who progressed within 9 months from beginning 
of single-line treatment (median OS 10.9 versus 
7.9 months; HR 0.75; 95% CI: 0.60–0.92; p = 
0.0073). Patient-reported outcomes for symp-
toms and quality of life (QoL) from the LUME-
Lung 1 are also encouraging, showing no 
detrimental effect on patients’ QoL [Novello et al. 
2015] and further supporting the use of such drug 
in this setting of patients.
At the same time, the REVEL phase III rand-
omized study investigated the addition of another 
anti-angiogenic agent, the anti-VEGFR2 mono-
clonal antibody, ramucirumab, to docetaxel in 
Table 1. Outcomes of nintedanib in the LUME-Lung 1 study.
Outcomes All histologies Adenocarcinoma
 (Nintedanib + docetaxel versus 
docetaxel)
(Nintedanib + docetaxel versus 
docetaxel)
ORR (%) 4.4 versus 3.3 N.A
DCR (%) 54 versus 41.3 N.A
mPFS 3.4 versus 2.7 months (HR 0.85, 95% 
CI 0.75–0.96, p = 0.0019)
4.2 versus 2.8 months (HR 0.84, 
95% CI 0.71–1.00, p = 0.0485)
mOS 10.1 versus 9.1 (HR 0.94, 95% CI 
0.83–1.05], p = 0.2720)
12.6 versus 10.3 (HR 0.83, 95% CI 
0.70–0.99, p = 0.0359)
DCR, disease control rate; mOS, median overall survival; mPFS, median progression-free survival; N.A, not available; 
ORR, objective response rate.
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NSCLC patients who failed prior platinum-based 
chemotherapy. The results of this trial have also 
shown a significant superiority of combination 
therapy versus docetaxel alone in the overall pop-
ulation, including both squamous and nonsqua-
mous histotypes [Garon et  al. 2014], thus 
confirming that combining angiogenesis inhibi-
tors with chemotherapy is an effective treatment 
strategy in the second-line setting. A careful anal-
ysis of the phase III LUME-Lung 1 and REVEL 
trials suggests that the characteristics of included 
patients were similar in both studies. In particu-
lar, the percentage of patients who received prior 
anti-angiogenic therapies, such as bevacizumab, 
was very low as was the number of elderly patients, 
while patients with performance status of 2 were 
not admitted in both the studies. Interestingly, a 
recent subgroup analysis of the LUME-Lung 1 
has shown that adenocarcinoma patients treated 
with nintedanib seem to maintain an OS benefit 
independently of prior first-line therapy with bev-
acizumab (median OS 14.9 versus 8.7 months; 
HR 0.61; 95% CI 0.31–1.20), even if it did not 
reach a statistical significance because of the small 
number of such patients [Heigener et al. 2015]. 
Information about EGFR mutation status was 
known in only 30% of patients in the REVEL 
study and in none of the patients in the LUME-
Lung 1 study (similarly for EML-ALK status), 
thus limiting any definitive consideration on the 
efficacy of both drugs in the subgroup of onco-
gene-addicted patients.
A similarly manageable tolerability profile has 
emerged from both studies, and data on QoL 
showed that it did not deteriorate with the addi-
tion of anti-angiogenic agents to chemotherapy. 
However, there are also differences in the safety of 
these two compounds. A significantly higher inci-
dence of gastrointestinal events, including diar-
rhea, nausea, vomiting and increases in liver 
enzymes was reported in the nintedanib plus doc-
etaxel arm compared with the control arm in the 
LUME-Lung 1 study. Adverse events usually 
associated to anti-angiogenic therapies, including 
bleeding/hemorrhage and hypertension occurred 
more frequently with the ramucirumab plus doc-
etaxel combination, while they did not signifi-
cantly increase with nintedanib [Reck et al. 2015]. 
The two anti-angiogenic drugs are different in 
terms of extension of OS benefit. In the LUME-
Lung 1 study, this benefit was limited to patients 
with adenocarcinoma histology, whereas in the 
REVEL study it was extended to the overall 
NSCLC population. However the percentage of 
patients with squamous histology and treated with 
ramucirumab were very low (25%) to demon-
strate the clinical efficacy of such agent in this sub-
set of patients. On the basis of such scientific 
evidence, nintedanib plus docetaxel has been 
recently approved by the EMA as a second-line 
treatment for patients with lung adenocarcinoma 
while ramucirumab plus docetaxel received US 
Food and Drug Administration (FDA) approval 
as a second-line option for the overall NSCLC 
population.
We recently proposed a new treatment algorithm 
describing the sequences of therapy from first to 
third-line for non-oncogene addicted adenocarci-
noma patients, suggesting the combination of 
both nintedanib and ramucirumab with docetaxel 
as a new standard second-line option in non 
elderly and Eastern Cooperative Oncology Group 
(ECOG) Performance Status (PS) PS 0–1 patients 
who progressed to first-line platinum regimens 
[Bronte et al. 2015]. To date, there are no clinical 
trials comparing both nintedanib and/or ramu-
cirumab plus docetaxel combinations with stand-
ard second-line options other than docetaxel. The 
comparisons between single-agent chemotherapy 
and the EGFR-TKI, erlotinib, suggested a poten-
tial survival benefit in favor of chemotherapy in 
EGFR wildtype NSCLC patients [Vale et  al. 
2015; Zhao et al. 2014; Osarogiagbon et al. 2015], 
thus providing indirect evidence about the superi-
ority of combination regimens over EGFR-TKI.
Even if the addition of nintedanib to pemetrexed 
in the LUME-Lung 2 study has led to controver-
sial results [Hanna et al. 2013], the fact remains 
that pemetrexed is currently used in combination 
with platinum as first-line treatment in most 
European patients with EGFR/ALK-WT lung 
adenocarcinoma. Therefore, it may be left out of 
the debate about the best second-line option in 
Europe, where the combination of nintedanib 
plus docetaxel may be considered as a new stand-
ard of care. For US patients, a direct comparison 
between single-agent pemetrexed and ramu-
cirumab plus docetaxel combination is needed to 
establish the best therapy for patients with nons-
quamous histology, who often do not receive 
pemetrexed first line. Currently, there are no stud-
ies which make a direct comparison between nint-
edanib and ramucirumab in NSCLC. However, 
nintedanib was registered by EMA for European 
patients, whereas ramucirumab was registered by 
FDA in the US. Hence, these two drugs can cur-
rently be prescribed in different populations.
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194 http://tam.sagepub.com
Place of nintedanib in the future treatment 
algorithm of NSCLC
As well as angiogenesis inhibition, immunother-
apy is emerging as another promising strategy in 
NSCLC. Several immune-checkpoint inhibitors, 
including both anti programmed death 1 (PD1) 
and anti programmed death-ligand 1 (PD-L1) 
monoclonal antibodies, have shown great activity 
in heavily pretreated NSCLC patients included in 
early phase I studies [Gettinger et al. 2015; Garon 
et al. 2015], reaching an objective response rate 
(ORR) close to 20%. Two randomized phase III 
studies (CheckMate 017 and 057) recently 
compared the anti-PD1 monoclonal antibody, 
nivolumab, versus docetaxel in pretreated NSCLC 
patients with squamous and nonsquamous histol-
ogy respectively, showing a significant survival 
improvement in favor of nivolumab in both stud-
ies [Brahmer et  al. 2015; Borghaei et  al. 2015]. 
On the basis of these positive results, nivolumab 
recently received FDA approval for the treatment 
of patients with squamous NSCLC after prior 
platinum-based chemotherapy and will probably 
receive approval for nonsquamous histology soon. 
Furthermore, pembrolizumab has also been 
approved by the FDA for treatment of advanced, 
PD-L1-positive NSCLC after other treatments, 
leading to an interesting debate regarding the best 
second-line option for non-oncogene addicted 
NSCLC patients in the near future.
The lack of a direct comparison between the 
immune-checkpoint inhibitors and the new 
standard second-line therapy, represented by nin-
tedanib and ramucirumab plus docetaxel combi-
nations along with the absence of long-term 
survival analysis from published studies, currently 
limits any evidence-based recommendation. In 
the meantime, a careful evaluation of the charac-
teristics of patients candidate to receive a second-
line therapy, including general health conditions, 
comorbidities, disease burden and tumor-related 
symptoms, responses and tolerability to the 
first-line therapy and concomitant medications, 
together with the drug’s activity and safety pro-
files emerging from clinical studies could help to 
choice the best option to each of them. Indeed 
adenocarcinoma patients ‘fit for chemotherapy’, 
including non-elderly patients with PS 0–1, with-
out significant comorbidities, who have tolerated 
first-line treatment well, or who have progressed 
within 9 months from beginning of first-line 
treatment could be the best candidates for nint-
edanib plus docetaxel combination in second-line. 
Conversely, older/PS2 people, current/former 
smokers or patients who experienced hematologi-
cal toxicities from first-line therapy should receive 
immunotherapy as preferred option, excluding 
those with viral hepatitis or autoimmune disease 
or CNS symptomatic metastasis in treatment 
with steroids who are not eligible for such kind of 
treatment. However, strong evidence about the 
efficacy of immunotherapy in these subsets of 
patients have not been available yet.
Furthermore, we have evidence about the activity 
of immune-checkpoint inhibitors in NSCLC after 
second-line treatment [Besse et al. 2015], but we 
do not have that data for nintedanib. This should 
also be taken into account in the design of a poten-
tial treatment algorithm in order to offer all the 
treatment options available to our patients and ulti-
mately try to extend their survival outcomes. On 
the basis of such available evidence, we propose 
here a new treatment algorithm describing the 
sequence of therapy from first-line to third-line 
treatment for non-oncogene addicted adenocarci-
noma patients, including also the new immune-
checkpoint inhibitors which will be approved early 
for this setting of patients (Figure 2). Based on 
studies mostly on immune-checkpoint inhibitors 
in NSCLC, a recent pooled analysis performed 
by our group has recently confirmed that tumor 
PD-L1 expression is significantly associated with 
higher ORR in pretreated NSCLC receiving differ-
ent anti-PD1 or anti-PD-L1 monoclonal antibod-
ies [Passiglia et al. 2015b]. The identification and 
clinical validation of reliable predictive biomarkers 
for both anti-angiogenic treatments and immuno-
therapies is likely to help oncologists to select the 
best therapy for each patient in the near future.
Conclusion
For a long time, a slight improvement of NSCLC 
prognosis has been achieved by standard chemo-
therapy. In this context, platinum-based regimens 
represented the backbone for first-line treatment. 
The findings about the impact of pro-angiogenic 
markers on NSCLC natural history yielded the 
addition of bevacizumab to standard first-line 
chemotherapy for patients with nonsquamous 
histology. However, a striking antitumor effect 
and a sizeable outcome improvement have been 
observed only with the introduction of TKIs for 
targetable oncogenic drivers.
In this landscape of novel treatments for NSCLC, 
nintedanib provides the opportunity to improve 
outcomes for docetaxel-based second-line therapy 
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for patients with adenocarcinoma. Fortunately, 
this achievement has been obtained at the expense 
of manageable higher rates of hematological and 
gastrointestinal toxicity. For this reason, nint-
edanib should be considered for patients with 
adenocarcinoma who can undergo second-line 
chemotherapy.
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